Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989592 | 0.91 | SLC6A9 (0.42) | SLC6A2SLC6A4SLC6A3SLC6A9CYP3A4 | |
| SCHEMBL989583 | 0.91 | CCR1 (0.41) | SLC6A9CYP3A4F2NR1I2HSD11B1 | |
| SCHEMBL988781 | 0.89 | SLC6A9 (0.41) | SLC6A2SLC6A4SLC6A3SLC6A9CYP3A4 | |
| SCHEMBL989128 | 0.88 | ALDH1A1 (0.43) | SLC6A9CYP3A4F2 | |
| SCHEMBL990531 | 0.88 | CCR1 (0.44) | SLC6A9CYP3A4F2 | |
| SCHEMBL990093 | 0.87 | MEN1 (0.48) | SLC6A9CYP3A4F2 | |
| SCHEMBL989660 | 0.87 | HSD11B1 (0.36) | SLC6A2SLC6A4SLC6A3SLC6A9CYP3A4 | |
| SCHEMBL1078429 | 0.86 | SLC6A9 (0.50) | SLC6A9CYP3A4NR1I2HSD11B1 | |
| SCHEMBL990394 | 0.86 | SLC6A9 (0.40) | SLC6A9CYP3A4NR1I2HSD11B1 | |
| SCHEMBL989820 | 0.85 | KMT2A (0.47) | SLC6A9CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | SLC6A2 49/4885SLC6A4 61/4885SLC6A3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.